Stay updated on P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.

Latest updates to the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page
- Check4 days agoChange DetectedThe revision tag was updated from v3.6.3 to v3.6.4, indicating a new content release.SummaryDifference0.1%

- Check11 days agoChange DetectedNew entries were added to the Study Record Dates for 2026-07-16, 2027-04-08, 2026-06-25, and 2026-06, and older dates 2025-07-20, 2026-05-04, 2025-07-09, and 2025-07 were removed. These changes update the historical timeline of the study record on the page.SummaryDifference0.3%

- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedThe page revision changed from v3.6.2 to v3.6.3, indicating a small update to the page’s versioning or metadata rather than any changes to the study details.SummaryDifference0.1%

- Check33 days agoChange DetectedThe page revision tag was updated from v3.6.0 to v3.6.2, indicating a software update to the page rendering. This likely reflects backend/frontend improvements and does not modify the study information.SummaryDifference0.1%

- Check48 days agoChange DetectedNew user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) and a recruitment-status note have been added. The Intervention/Treatment label remains visible and the revision version updated to v3.6.0, reflecting a refresh of the study details and navigation.SummaryDifference0.5%

- Check55 days agoChange DetectedThe page shows an updated revision label from v3.5.4 to v3.5.5, reflecting a version update rather than a change to the study details.SummaryDifference0.1%

Stay in the know with updates to P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.